CorNeat Vision is an Israeli medtech startup that has developed a synthetic cornea as a cure for blindness. CorNeat raised $4 million from the Guangzhou Sino-Israel Biotech Investment Fund (GIBF).
CorNeat intends to invest the new funding in its Chinese subsidiary Guangzhou, China. CorNeat plans to expand its activity in the Chinese market, including clinical trials, setting up a manufacturing facility, and marketing the company’s first two products.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Established in 2015 and based in Ra’anana, CorNeat Vision is an ophthalmic medical device company who declares its mission to be to promote human health, sustainability and equality worldwide. CorNeat Vision produces a lineup of innovative, safe, affordable and long-lasting ophthalmic medical solutions, including the CorNeat KPro and the CorNeat EverPatch. Its products can improve ophthalmic surgery practices in the areas of cornea, sclera, glaucoma (trabecular mesh), myopia and more.
The CorNeat KPro implant is designed to replace deformed, scarred or opacified corneas. The company states that this implant is expected to “fully and immediately rehabilitate” the vision of corneally blind patients following an implantation procedure. The CorNeat Boasts that its KPro will transform global corneal therapy and provide, for the first time, a reliable and scalable synthetic substitute to the human cornea, significantly impacting the lives of millions of people with cornea-related visual impairments and blindness.
In January, CorNeat successfully restored the vision of a 78-year-old man who had been blind for 10 years. The procedure was performed at the Rabin Medical Center in Israel.
The surgery was performed on a bilaterally blind patient by Professor Irit Bahar, Director of the hospital’s Ophthalmology Department.
CorNeat’s states that its lineup of biomimetic implants “blends novel bio-integration technology with innovative ideas to create groundbreaking solutions that address unmet needs in the areas of ophthalmology and periodontology.” Their products biomechanically incorporate with resident tissue providing safe, aesthetic and long-lasting remedies for corneally blind patients and those suffering from glaucoma. These include the CorNeat KPro (artificial cornea), the CorNeat EverPatch (synthetic tissue patch) and the CorNeat eShunt (glaucoma drainage device).
